🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

⛳️ To finish off 🙌🏼 the #PRIME milestones, we are proud to announce the fantastic recruitment of our UK sites 🇬🇧 throughout the past year and a bit! 🚀✨ 🌟 CamUrology: 3️⃣5️⃣➕ 🌟 UCLH: 2️⃣5️⃣➕ 🌟 Royal Free London: 5️⃣➕ #UroSoMe #prostatecancer #prostateMRI

This is an interesting Would be interesting to read through the paper

'Focussed' progression is the key. 'Target' being the prostate! Skill upgradation. Guided by world leaders. UCLH Caroline Moore John Withington Veeru Kasi @ClementOrczyk Alistergrey Mark Emberton

Despite losing the first Test, #TeamIndia bounced back impressively to clinch the series with a comfortable 4-1 scoreline. Throughout the series, the team has capitalised on every opportunity presented to them. Kuldeep yadav and Ashwin 🇮🇳's outstanding performances were

Times Algebra The proudest moment for a 💕mother is when her son comes in front of her wearing army dress 🙏 Jai Hind

Do we still need contrast in our MRIs for Prostate Diagnostics ?! Eagerly waiting for answers and looking forward to it. Veeru Kasi Caroline Moore

🚨 Breaking results 🚨 @PrimeMRI study presented at #EAU24 European Association of Urology (EAU). This 🌍 multicentre trial (n=555, 22 sites) showed that biparametric MRI without contrast is non-inferior 2 multiparametric MRI & should be the new standard for prostate cancer diagnosis if image quality is good

Prostate calcifications are deterrents for post gland treatment modalities like #HIFU paving the way for more effective anterior gland treatment modalities of #cryotherapy and #Nanoknife ⁦⁦Focal Therapy Society⁩ ⁦FOCAL+ 2025⁩ ⁦Focal.Therapy.UK⁩ ⁦Abhinav Sidana⁩

🎯Is Focal Therapy ready for prime time?!? 🕰️ There is still time to join the great debate Indian American Urological Association 🤺The duel with DrBagrodia starts at 9:30am 🏠 ROOM 205 #AUA24 Amer. Urol. Assn. Ganesh Palapattu Abhinav Sidana

Things taught at the Amer. Urol. Assn. #AUA2024 1- focal therapy is not about pushing a button! 2- Understand the biology of cancer 3- Imaging, Patient Selection and Follow up matter! September 19-22 2024 Endourological Society Society of Urologic Robotic Surgeons (SURS) meetings.association-service.org/fts/joint

Intermediate-risk disease who elected primary PGCA, the five-year freedom-from-failure rate was 91 percent. This includes near- and in-field recurrences 2/3 with int-risk CaP would opt for CRYO over radical surgery.🚨 This is huge 👍🏻☑️ @ibus Urological Society of India 🇮🇳 USI Board of Educati Dr Ravimohan

Nice work Aqua Asif @PrimeMRI

BAUS @ Birmingham. Making new connections. Revisiting old ones. Knowledge exchange ! ⁦IBUS⁩ ⁦Mark Emberton⁩ @PeaPeaspot⁩ ⁦Joe Philip 🇮🇳 🇬🇧⁩ ⁦Urological Society of India 🇮🇳⁩ ⁦Vattikuti Foundation⁩ ⁦YOUsi⁩ ⁦Caroline Moore⁩ ⁦🇮🇳 Bhavan Rai 🇬🇧⁩ ⁦⁦

Attended a fantastic CME on NanoKnife by ⁦Aquilant Oncology⁩. It was an incredible opportunity to learn from and interact with world leaders in the field. @therap_focal Focal Therapy Society @UKFocal John Withington Mark Emberton Abhinav Sidana Arvin K. George, MD Urological Society of India 🇮🇳

🎉Congratulations to the #IP6CHAIROS study team for successfully completing recruitment of over 6️⃣0️⃣0️⃣ patients! Imperial Prostate @NIHRCRNWessex UCLH UHCW NHS Trust Chelsea and Westminster Hospital West Middlesex University Hospital Let’s keep the momentum going until completion! 💪🏻💯

Looking forwards to ⁦Abhinav Sidana⁩ ⁦Mark Emberton⁩ ⁦Focal Therapy Society⁩ ⁦Sonablate Corp.⁩ ⁦AngioDynamics, Inc.⁩ #focal-therapy #HIFU #Cryoablation #nanoknife ⁦Gagan Gautam⁩ ⁦Vattikuti Foundation⁩ Robotic Surgery

An incredible session on AI from treatment and beyond of prostate cancer by Dr. Giovanni E Cacciamani MD MSc FEBU 🇮🇹🇺🇸🇪🇺 with very informative talks Mount Sinai Department of Urology Michael Gorin, M.D. Girish Nadkarni Prof. Prokar Dasgupta OBE Ash Tewari, MD

🚀 Does More Biopsy = Better Outcomes in Focal Therapy? 🔍 Our #EAU25 study challenges the assumption that higher biopsy sampling density improves recurrence prediction. Findings suggest MRI visibility—not biopsy density—drives patient selection & outcomes.

🏆 Humbled to receive the Best Poster Prize at #EAU25! 🎉 Our study challenges the idea that more biopsy = better outcomes in focal therapy. Findings suggest MRI visibility—not biopsy density—drives recurrence risk. #ProstateCancer #FocalTherapy #Urology #CancerResearch @